< Previous50FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Saturday, 23 April 2022 O0235Reduced chlorhexidine susceptibility in invasive Klebsiella pneumoniae ST258 bla KPC2- producing isolates M. Roch* (Geneva, Switzerland), R. Sierra, A.C. Gales, D.O. Andrey O0236Emerging threat of carbapenem-resistant and hypervirulent Klebsiella pneumoniae in healthcare setting, South Korea: a retrospective observational, single-centre study M.J. Kim* (Seoul, Korea, Republic of), Y.S. Chung, Y. Jeong O0237Molecular surveillance of NDM-5-producing Escherichia coli revealed the countrywide dissemination of certain high-risk clones in Germany, 2013 to 2019 J.B. Hans* (Bochum, Germany), N. Pfennigwerth, B. Neumann, Y. Pfeifer, M.A. Fischer, J. Eisfeld, J. Schauer, S. Gatermann, G. Werner O0238Molecular features and transmission of NDM- producing Enterobacterales in Israeli hospitals A. Adler* (Tel Aviv, Israel), H. Ghosh, A. Gross, A. Rechavi, M. Lasnoy, M. Assous, Y. Geffen, M. Paul, Y. Wiener-Well, S. Reuter, H. Grundmann O0239High prevalence of OXA-23 carbapenemase- producing Proteus mirabilis among amoxicillin- clavulanate-resistant isolates in France L. Dortet* (Le Kremlin-Bicêtre, France), A. Lombes, R.A. Bonnin, F. Laurent, H. Guet-Revillet, E. Bille, V. Cattoir, M.S. Fangous, C. Le Brun, V. Fihman, F. Janvier, A. Potron, S. Corvec, A. Mizrahi OS05816:15 - 18:15Hall H 2-Hour Oral Session Current treatment approach to COVID-19 ChairsDominique Braun (Zurich, Switzerland) Karine Lacombe (Paris, France) O0240Safety and feasibility of monoclonal antibody therapies in children with SARS-CoV-2 infection L. Romani* (Rome, Italy), S. Bernardi, S. Chiurchiu’, L. Cursi, F.I. Calò Carducci, M. Di Giuseppe, M. De Luca, L. Vallesi, A. Smarrazzo, P. Merli, A. Campana, L. Lancella, E. Nicastri, P. Palma, M. Raponi, P. Rossi O0241Antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital- acquired COVID-19: a single-centre experience A. Faraone* (Florence, Italy), T. Picchioni, G. Scocchera, P. Carrai, A. Lo Forte, S. Sbaragli, M. Bettucchi, A. Fortini O0242Impact of using steroids and interleukin (IL-1 and IL-6) inhibitors on secondary infections and fatality in severe and critical COVID-19 cases Ö. Ergönül* (Istanbul, Turkey), E. Er Gülbezer, M. Kapmaz, P. Irkören, M.G. Gönenli, S. Iliaz, B. Dikenelli, E. Sentürk, S. Tekin, N. Alpay Kanitez O0243Dual monoclonal antibodies in SARS-CoV-2 infected patients: clinical and virological efficacy N. Peiffer-Smadja* (Paris, France), L. Kramer, V.M. Ferré, R. Coppée, A. Kanté, M. Debarge, C. Choquet, T. De Saint Joannis, D. Bouzid, J. Messika, J. Le Grand, M. Thy, S. Kerneis, D. Descamps, J. Ghosn, B. Visseaux O0244Synergistic inhibitory effect of remdesivir and ribavirin against human coronavirus 229E C. García-Crespo* (Madrid, Spain), A.I. De Ávila, I. Gallego, M.E. Soria, B. Martínez-González, L. Vázquez-Sirvent, E. Domingo, C. Perales O0245Use of high-dose casirivimab/imdevimab to treat anti-spike seronegative patients hospitalised with COVID-19: first experiences from a tertiary care centre in Florence, Italy T. Manciulli* (Florence, Italy), M. Spinicci, A. Barbiero, R. Paggi, A. Miftode, M. Tilli, S.T. Kiros, J. Mencarini, F. Lagi, N. Di Lauria, L. Zammarchi, A. Bartoloni O0246Impact of home treatment with glucocorticoids in patients with COVID-19 pneumonia E. Franceschini* (Modena, Italy), A. Dessilani, A. Cozzi-Lepri, V. Iadisernia, M. Digaetano, G. Cuomo, E. Bacca, F. Carli, M. Menozzi, G. Guaraldi, C. Mussini O0247Real-world baricitinib use in critically ill patients with COVID-19 during tocilizumab shortage at a large academic health-system in Miami, Florida K.J. Deronde* (Miami, United States), A.D. Vega, C.A. Vu, R. Boatwright, J.C. Simon, V. Salazar, C.M. Mauriello, E. Cano, R. Rosa, L.M. Abbo O0248Tocilizumab treatment in adult patients with moderate to critical COVID-19 pneumonia: a retrospective study in a teaching hospital of infectious diseases, Cluj-Napoca, Romania M. Muntean* (Cluj-Napoca, Romania), A. Radulescu, A. Istrate, A. Csiszer, R. Dobrota O0249Clinical effectiveness of REGN-COV2, a neutralising antibody cocktail in patients with COVID-19 in Japan: a retrospective cohort study with a bayesian inference N. Amano* (Kakogawa, Japan), S. IwataScientific Programme 51FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Saturday, 23 April 2022 ESCMID presents: EUCAST at ECCMID 2022 Saturday, 23 April 2022 08:30 - 11:30Hall A Educational Workshop EUCAST Educational Workshop Chairs Alasdair P. Macgowan (Bristol, United Kingdom) Arjana Tambi ć -Andraševi ć (Zagreb, Croatia) 08:30EUCAST Update Christian Giske (Stockholm, Sweden) 09:00Putting certainty into antimicrobial susceptibility testing Gunnar Kahlmeter (Växjö, Sweden) 09:30PK/PD breakpoints in the EUCAST breakpoint tables Shampa Das (Liverpool, United Kingdom) 10:00Revising aminopenicillin breakpoints John D. Turnidge (Hawthorn, Australia) 10:30Screening and testing for antifungal resistance Maiken Arendrup (Copenhagen, Denmark) Co-organised with: EUCAST Steering Committee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) Sunday, 24 April 2022 07:15 - 08:15Hall I Meet-the-Expert EUCAST Frequently Asked Questions 07:15Erika Matuschek (Växjö, Sweden) 07:45Mandy Wootton (Cardiff, United Kingdom) Co-organised with: EUCAST Steering Committee Sunday, 24 April 2022 11:00 - 12:00Hall N Symposium Updates on antimicrobial susceptibility testing of mycobacteria ChairsThomas Schön (Kalmar, Sweden) Florian Maurer (Borstel, Germany) 11:00Updates and open questions on the recently revised WHO critical concentrations for antimicrobial susceptibility testing of Mycobacterium tuberculosis complex Claudio Köser (Cambridge, United Kingdom) 11:30The EUCAST approach for drug susceptibility testing of mycobacteria: past, present, future Emmanuelle Cambau (Paris, France) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), EUCAST Subcommittee on Antimycobacterial Susceptibility Testing (EUCAST-AMST)52FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Overview Sunday, 24 April 2022 All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Hall AHall BHall CHall DHall EHall F 07:15 - 08:1507:15 - 08:15 ME059ME060 Externalquality assessment in microbial genomics Nosocomial transmis- sion of SARS-CoV-2: have you looked at all the risks? 08:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 09:3008:30 - 10:3008:30 - 10:30 KN067SY068SY069OS077SY070SY071 Excellence Award lectures New developments in antimicrobial resistance and virulence of anaerobic pathogens Different perspectives on infectious diseases diagnostics in LMICs Challenges associated with Capnocytophaga infections COVID-19: vaccinating the whole world? Update on the WHO strategy to eliminate viral hepatitis 11:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:00 KN080OS086SY081OS090SY082SY083 Rapid detection of emerging SARS-CoV-2 variants Hepatitis E: an update Unusual fungal infections from around the globe Fightingbiofilmwith non-traditional anti- bacterials Dealing with the complexity of pandemics: the future is now Year in Infectious Diseases 13:30 - 14:3013:30 - 15:3013:30 - 15:3013:30 - 14:3013:30 - 15:3013:30 - 15:30 KN096SY097EW100OS104SY098EW101 Subacute and chronic meningitis Challenging mycobacterial infections Don’t get lost in translation: the use of preclinical PK/PD models in anti-infec- tive drug develop- ment Never let an outbreak go to waste: how COVID-19 has changed hospital epidemiology and infection prevention and control Impact of rapid diagnostics for community-acquired acute respiratory tract infections (CA- ARTI) on antibiotic stewardship Vaccinated or non- vaccinated: patients are not healthcare workers,andtheflu is not COVID-19 14:45 - 15:4514:45 - 15:45 KN107OS111 Management of orthopaedic infections AI revolution in medicine 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:15 SY114SY115OS120SY116SY117 Sepsis biomarkers: from gene to score Emerging priorities and developments for antifungals and fungal infections Late-breaking research from The Lancet group Updates on HIV treatment and prevention Host and viral factors in COVID-19, what makes us sick? IDID ID IDID CM CM CMCM CM CMCM IC IC PH PH PH PHScientific Programme 53FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Hall GHall HHall IHall JHall KHall L 07:15 - 08:1507:15 - 08:1507:15 - 08:1507:15 - 08:15 ME061ME062ME063ME064 Getting to yes: strengthening vaccine uptake in hard-to-reach and vaccine hesitant communities Diagnosis and treatment of herpes simplex encephalitis EUCASTFrequently Asked Questions Current approaches to prevent invasive fungal diseases in pediatric patients 08:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:30 OS074OS075EW073SY072OS076IS15 SARS-CoV-2 transmis- sion in healthcare environments: detec- tion and prevention Clinical PK/PD studies and TDM to improve dosing of anti-infectives Optimising the use of antibiotics for neo- nates and children Supporting evidence in infection prevention and control: 2022 ESCMID guidelines Endocarditis, mice and men After the COVID-19 tide: exploring novel approaches in infectious diseases diagnostics from syndromic to immune testing 11:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:00 OS087OS088SY084OF091OF092 UTI: from mild to complicated, from diagnosis to treatment Resistance markers in sexually transmitted bacteria Combination therapies: from models to patients New insights into pathogens virulence: human and microbial factors Pathogenesis of fungal infections: the host and pathogen point of view 12:15 - 13:15 IS19 Control disease immediately: think C. difficle infection, think COVID! 13:30 - 15:3013:30 - 14:3013:30 - 14:3013:30 - 14:3013:30 - 15:30 EW102OF105SY099OF106IS24 The changing epide- miology of West Nile fever virus in Europe Optimising treatment of invasive fungal infections in critically ill patients How to use intervention and implementation research to mitigate AMR Epidemiology of parasites, here and there All about intracellular and rare bacteria 14:45 - 15:4514:45 - 15:4514:45 - 15:4514:45 - 15:45 SY108OS110SY109OF112 Elimination of HBV and HCV The changing picture of childhood pneumonia Imported cutaneous leishmaniasis in Europe by the thousand: is it all the same? Update on epidemiology and resistance in Staphylococcus aureus and Enterococcus 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:15 OS121OS122EW118EW119OS123IS28 The different faces of Lyme borreliosis How to make clinical trialsmoreefficient Innovative and scal- able molecular solu- tions for infectious disease testing Genomic epidemiology of nosocomial infections AMR Acinetobacter, Pseudomonas and Salmonella: what is new? What’s fast, new and relevant in infectious disease diagnostics? ID ID ID ID IDID ID ID CM IC PH PH PH Colour Key Educational Workshops, Meet-the-Expert Sessions Sessions specifically interesting for: Infectious Disease specialists Symposia (1h/2h)Oral sessions (1h/2h) Keynote Lectures Clinical Microbiologists Infection Control specialistsPublic Health specialists CM IDIC Open Forum & Virtual Walk Throughs PH Integrated Symposia & Pipeline Corners are not detailed in this book. Please refer to the Industry Guide for session details.54FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Overview Sunday, 24 April 2022 All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Hall MHall NHall OHall PHall Q 07:15 – 08:1507:15 – 08:15 ME065ME066 Contact precautions and cleaning for MDR preven- tion FDG-PET/CT and outcome of infections in immuno- suppressed patients 08:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:30 IS16IS14IS17IS18 Spotlight on antifungals: arewewellequippedfor treating invasive fungal disease? Conquerthe case: integrating microbiological testing and the immune status of the host into clinical decision making Facing a ‘new normal’: co- existence of SARS-CoV-2 and respiratory viruses A Moment to Reset: harnessing learnings to tackle antimicrobial resistance in the community 11:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:00 OF093SY085OF094OS089 Updates on antimicrobial susceptibility testing of mycobacteria New faces in the camp of AMR pathogens Pathophysiology and prognosis in COVID-19 infection COVID-19 vaccine immuno- genicity and effectiveness in the immune compro- mised host 12:15 - 13:1512:15 - 13:1512:15 - 13:1512:15 - 13:15 IS20IS21IS22IS23 Staying ahead of the virus: evolving preventative strategies to manage COVID-19 variants Rapid AST on positive blood cultures: new stan- dards in rapid susceptibili- ty testing? Time to rethink NTM: understanding your at- risk MAC-PD patients and optimising their outcomes Intravenous fosfomycin: comprehensive new data evaluation for this WHO essential antibiotic for... 13:30 - 15:3013:30 - 15:3013:30 - 15:3013:30 - 15:3013:30 - 15:30 OS103IS25IS25AIS26IS27 Moving insights into action: how innovative rapid diagnostics impact treatment decisions Evolution of rapid metagenomics for infectious disease applications Future-proofingmould disease diagnosis and treatment: the post-pan- demic era COVID-19 today: outpatient treatment options and considerations The Public Health response to COVID-19 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:15 IS29IS30IS31IS32 Reviewing 20 years of managing invasive mould infections: lessons learned and remaining challenges RSV burden: the need for all infant protection New data, fresh perspectives: an update on CAP and SSTI In light of the COVID-19 pandemic: how can new antibiotics help reduce the pressure on hospitals and facilitate early discharge? ID CM ICScientific Programme ID, ember 2018, gn: www. terfolg.de ESCMID THE FIRST 35 YEARS 1983– 2018 How it all began. Learn this and more in the brochure „the first 35 years“ Brochure available at https://www.escmid.org/membership_organisation/ about_escmid/history/ Arena 1 & 2 Session TimeSessionArena 08:30 - 09:30VW078Virtual Walk ThroughMultiple drug-resistant bacteria and COVID-19: a double whammy2 09:30 - 10:30VW079Virtual Walk ThroughStaphylococcus aureus, a long way to the top1 12:15 - 13:15FO095Open ForumIs Twitter the new ID textbook?1 12:15 - 13:15FO095AOpen ForumWhensciencegetspoliticised;experiencesfromtheCOVID-19pandemic2 14:45 - 15:45VW113Virtual Walk ThroughEfficacyandimmunityofestablishedvaccines2 16:15 - 17:15VW124Virtual Walk ThroughStandardised methods for antimicrobial susceptibility testing2 Colour Key Educational Workshops, Meet-the-Expert Sessions Sessions specifically interesting for: Infectious Disease specialists Symposia (1h/2h)Oral sessions (1h/2h) Keynote Lectures Clinical Microbiologists Infection Control specialistsPublic Health specialists CM IDIC Open Forum & Virtual Walk Throughs PH Integrated Symposia & Pipeline Corners are not detailed in this book. Please refer to the Industry Guide for session details.56FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Sunday, 24 April 2022 CM ME05907:15 - 08:15 Hall C Meet-the-Expert External quality assessment in genomics M025007:15Aitana Lebrand (Geneva, Switzerland) M025107:45Denise O’Sullivan (London, United Kingdom) Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), ESCMID Study Group for Epidemiological Markers (ESGEM) IC ME060 07:15 - 08:15 Hall F Meet-the-Expert Nosocomial transmission of SARS-CoV-2: have you looked at all the risks? M025207:15Emine Alp Mese (Ankara, Turkey) M025307:45Michihiko Goto (Iowa City, United States) PH ME061 07:15 - 08:15 Hall G Meet-the-Expert Getting to yes: strengthening vaccine uptake in hard-to- reach and vaccine hesitant communities M025407:15Sally Hargreaves (London, United Kingdom) M025507:45Stephanie Vandentorren (Paris, France) Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) ID ME062 07:15 - 08:15 Hall H Meet-the-Expert Diagnosis and treatment of herpes simplex encephalitis M025607:15Oguz Resat Sipahi (Izmir, Turkey) M025707:45Jean Paul Stahl (Corenc, France) Co-organised with: Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD) CM ME063 07:15 - 08:15 Hall I Meet-the-Expert EUCAST Frequently Asked Questions M025807:15Erika Matuschek (Växjö, Sweden) M025907:45Mandy Wootton (Cardiff, United Kingdom) Co-organised with: EUCAST Steering Committee ID ME06407:15 - 08:15 Hall L Meet-the-Expert Current approaches to prevent invasive fungal diseases in paediatric patients M026007:15Andreas H. Groll (Münster, Germany) M0260A07:45Maria Elena Santolaya (Santiago, Chile) IC ME065 07:15 - 08:15 Hall N Meet-the-Expert Contact precautions and cleaning for MDR prevention M026107:15Stephanie J. Dancer (Glasgow, United Kingdom) M026207:45Gonzalo Bearman (Richmond, United States) Co-organised with: EUCIC Steering Committee ID ME066 07:15 - 08:15 Hall P Meet-the-Expert FDG-PET/CT and outcome of infections in immunosuppressed patients M026307:15Nesrin Ghanem-Zoubi (Haifa, Israel) M026407:45Alfred O. Ankrah (Accra, Ghana) Co-organised with: ESCMID Study Group for Immunocompromised Hosts (ESGICH), International Immunocompromised Host Society (ICHS) Presentations in light grey were not registered at the time of publishing.Scientific Programme 57FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 KN06708:30 - 10:30 Keynote lecture Excellence Award lectures Chairs Jesús Rodríguez-Baño (Seville, Spain) Maurizio Sanguinetti (Rome, Italy) KN026508:30 Characterising SARS-CoV-2, the virus that caused the COVID-19 pandemic: an ongoing effort Bart Haagmans (Rotterdam, Netherlands) Bart Haagmans is a virologist working at the Viroscience department, Erasmus medical center in Rotterdam, Netherlands. His research line focusses on the pathogenesis of viral infections and especially those viruses that emerge through zoonotic transmission, as a basis for (future) interventions and medical countermeasures. This brings together work performed earlier at the Veterinary faculty in Utrecht and more recent work on human viruses in Rotterdam. He brings a strong track record of fundamental and applied research of MERS-CoV, SARS-CoV and SARS-CoV-2. In collaboration with internationalteams,thenovelcoronaviruswasclassifiedas SARS-CoV-2, diagnostic assays were developed and validated while animal and in vitro organoid models were set up to further understand pathogenesis and test (antibody based) intervention strategies. Development of reagents, vaccines and protocols for molecular and serological detection of these emerging viral pathogens lead to options for interventions and medical countermeasures. Dr. Haagmans has more than 230 publications on different subjects in (clinical) virology, identificationandcharacterizationofnovelemergingviruses and the development of vaccines. He is an expert consultant of WHO, FAO and OIE on coronaviruses as well as a member of the the Coronaviridae Study Group of the ICTV. He is PI on several Dutch and EU grants and is co-coordinating the IMI ZAPI project, focused on zoonotic anticipation and preparedness initiatives, and amongst others led to discovery of broadly cross- reactive monoclonal antibodies against beta coronaviruses. Fireplace Session24 April, 11:00 - 12:00 Hall A Excellence Award lectures Chairs Jesús Rodríguez-Baño (Seville, Spain) Maurizio Sanguinetti (Rome, Italy) K026609:30Transcending European clinical research in infectious diseases through collaboration to break down traditional silos Herman Goossens (Edegem, Belgium) Prof. Herman Goossens is a full professor of Medical Microbiology at the University of Antwerp in Belgium since 1992, director of the laboratory of Clinical Microbiology at the University Hospital Antwerp since 1992 and director of Laboratory Medicine of the University Hospital Antwerp since 1997. His professional goal is to bridge the gap between basic and clinical research, with a major focus on antibiotic resistance, to enhance the standard of healthcare, public health and professional standards, for the good of the public in large. Prof.Goossens’scurrentresearchisfocusedonfiveareas. First, the detection and genetic mechanisms involved in the emergence and evolution of antibiotic resistance and virulence in bacteria and its epidemiological and ecological bases and implications. Second, studying antimicrobial use in hospitals, the community and long-term care facilities, developing indicatorsofuseandqualityofprescribing,initiallyinEurope, later globally, focusing on Low and Middle Income Countries. Third,linkingscientificandclinicalresearchthroughoutEurope in lower respiratory tract infections, in primary health care and hospital medical practice. Fourth, better preparing Europe for emerging infectious diseases and pandemics. Fifth, building a network of more than 800 diagnostic labs in more than 40 countries in Europe to support clinical trials that investigate the utility of new antimicrobial strategies and diagnostics. Prof. Goossens authored more than 600 Web of Science cited papers, and his papers have been cited close to 25,000 times. In 2008 Prof. Goossens obtained the prestigious status of Methusalem top-scientist from the Flemish government. Fireplace Session24 April, 11:00 - 12:00 Sunday, 24 April 202258FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 CM SY068 08:30 - 10:30 Hall B Symposium New developments in antimicrobial resistance and virulence of anaerobic pathogens ChairsAlida C.M. Veloo (Groningen, Netherlands) Edit Urbán (Pécs, Hungary) S026708:30EUCAST recommended method for antimicrobial susceptibility testing of anaerobic bacteria Erika Matuschek (Växjö, Sweden) S026809:00Carbapenem and metronidazole resistance mechanisms of Bacteroides Jozsef Soki (Szeged, Hungary) S026909:30Bacteroides fragilis: a tale of two habitats Sheila Patrick (Belfast, United Kingdom) S027010:00One step further: complementing phenotypical susceptibility testing and typing of Bacteroides using whole genome sequencing Thomas Vognbjerg Sydenham (Odense, Denmark) Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI) CM SY069 08:30 - 10:30 Hall C Symposium Different perspectives on infectious diseases diagnostics in LMICs ChairsElsie Ilori (Abuja, Nigeria) Michael L. Wilson (Denver, United States) S027108:30Overview of The Lancet Commission on Diagnostics Mikashmi Kohli (Geneva, Switzerland) S027209:00Developing a national essential diagnostics list Kamini Walia (New Delhi, India) S027309:30Current diagnostic capacities, and the impact of COVID-19 in LMICs Adeola Fowotade (Ibadan, Nigeria) S027410:00Review of the contribution of mobile laboratories in the response to outbreaks of VHFs and the COVID-19 pandemic Sayed Shahin (Nairobi, Kenya) Co-organised with: The Lancet Commission on Diagnostics PH SY070 08:30 - 10:30 Hall E Symposium COVID-19: vaccinating the whole world? ChairsNicola Petrosillo (Rome, Italy) Makeda Semret (Montreal, Canada) S027508:30Challenges to reach everyone on Earth Yazdan Yazdanpanah (Paris, France) S027609:00COVID-19 vaccination roll-out: equal access to COVID-19 vaccines and vaccinating hard-to-reach populations Jose Tuells (Alicante, Spain) S027709:30COVID vaccines acceptance and hesitancy Marco Safadi (São Paulo, Brazil) S027810:00Rethinking the ethics of vaccination and use of facemasks: balancing public good with human rights considerations Raquel Duarte (Porto, Portugal) Co-organised with: ESCMID Professional Affairs Subcommittee, ESCMID Study Group on Vaccines (EVASG), ESCMID International Affairs Subcommittee (EIAS), World Association for Infectious Diseases and Immunological Disorders (Waidid) PH SY071 08:30 - 10:30 Hall F Symposium Update on the WHO strategy to eliminate viral hepatitis ChairsArjan Harxhi (Tirana, Albania) Adriana Vince (Zagreb, Croatia) S027908:30The 2021 WHO global progress report Olufunmilayo Lesi (Lagos, Nigeria) S028009:00Monitoring progress towards the elimination targets in EU/EEA countries Erika Duffell (Stockholm, Sweden) S028109:30Viral hepatitis elimination in Turkey Nurcan Baykam (Çorum, Turkey) S028210:00HCV elimination in Egypt Manal Elsayed (Cairo, Egypt) Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH) IC SY072 08:30 - 10:30 Hall J Symposium Supporting evidence in infection prevention and control: 2022 ESCMID guidelines ChairsBiljana Carevic (Belgrade, Serbia) Priscilla Rupali (Velore, India) S028308:30Surgical prophylaxis in patients colonised with multidrug resistant Gram-negatives Evelina Tacconelli (Verona, Italy) S028409:00Surgical prophylaxis in patients colonised with multidrug resistant Gram-positives Jan A.J.W. Kluytmans (Utrecht, Netherlands) S028509:30Screening procedures in healthcare workers and patients during COVID-pandemic Anders Johansson (Umea, Sweden)Scientific Programme 59FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 S028610:00Preventing transmission of multidrug resistant Gram-negatives in hospitalised patients Nico Tom Mutters (Bonn, Germany) Co-organised with: EUCIC Steering Committee ID EW07308:30 - 10:30 Hall I Educational Workshop Optimising the use of antibiotics for neonates and children ChairsBojana Beovic (Ljubljana, Slovenia) TBA W028708:30Antibiotic use and stewardship in the PICU Hanna Renk (Tübingen, Germany) W028809:00Antibiotic use and stewardship in the NICU Angelika Berger (Vienna, Austria) W028909:30Surgical prophylaxis in neonates and children Elio Castagnola (Genoa, Italy) Co-organised with: European Society of Paedriatic and Neonatal Intensive Care (ESPNIC) OS074 08:30 - 10:30 Hall G 2-Hour Oral Session SARS-CoV-2 transmission in healthcare environments: detection and prevention ChairsGustavo Daniel Lopardo (Vicente Lopez, Argentina) Andreas Voss (Groningen, Netherlands) O0290Assessment of inhaled SARS-CoV-2 dose per particle size fraction in a standardised COVID-19 patient interaction: a patient proximity sampling study using a highly efficient respiratory particle collector dummy P. Jent* (Bern, Switzerland), E. Zimmermann, O. Al-Khalil, B. Sicre, M. Wider, A. Atkinson, P. Frey, F. Suter, R. Dijkman, J. Marschall O0291Investigation of a nosocomial SARS-CoV-2 cluster in immunocompromised patients by using the association of clinical and viral molecular data J. Andreani* (Grenoble, France), M. Gallouche, A. Caporossi, B. Nemoz, M. Le Maréchal, J. Lupo, H. Jardin, R. Germi, P. Morand, P. Poignard, C. Landelle, S. Larrat O0292SARS-CoV-2 Beta variant outbreak amongst a partially vaccinated long-term care facility population in the Netherlands: phylogenetic analysis and infection control observations N. Van Der Moeren* (Tilburg, Netherlands), V. Weterings, S.D. Pas, J.J. Verweij, W. Van Den Bijllaardt, V.V.F. Zwart, J.A.J.W. Kluytmans, J.L.A.N. Murk, J.J.J.M. Stohr O0293Whole genome sequencing of SARS-CoV-2 to support infection prevention and control practices in the management of acute hospital outbreaks M. Lucey* (Galway, Ireland), E. Mcgrath, S. Whelan, F. Higgins, B. Hanahoe, D. Judith, R. Waldron, U. Ni Riain, M. Cormican, D. Keady O0294A WHO multi-centre case-control study assessing the risk factors for COVID-19 infection in health workers A. Simniceanu* (Geneva, Switzerland), M. Yin, G. Gon, B. Allegranzi, A. Cassini O0295Contextual hospital conditions and the risk of nosocomial SARS-CoV-2 infection: a matched case-control study with density sampling in a large Portuguese hospital F. Almeida* (Porto, Portugal), S. Correia, C. Leal, R. Duro, N. Rocha-Pereira, P. Andrade, S. Pereira, C. Alves, A. Azevedo O0296Estimating the return on investment in selected infection prevention and control interventions in healthcare settings to limit the burden of SARS- CoV-2 A. Cassini* (Geneva, Switzerland), E. Ozcelik, A. Lerouge, B. Allegranzi, M. Cecchini O0297Decentralised sequencing and unified bioinformatics for SARS-CoV-2 outbreak monitoring K. Steinke* (Odense, Denmark), L. Andersen, S.L. Larsen, S.V. Høgh, K.G. Thomsen, M.N. Skov, T.V. Sydenham O0298Reconstructing transmission chains of SARS- CoV-2 amid multiple outbreaks in a geriatric acute-care hospital M. Abbas* (Geneva, Switzerland), A. Cori, S. Cordey, F. Laubscher, T. Robalo Nunes, J. Salamun, P. Huber, D. Zekry, V. Prendki, A. Iten, L. Vieux, V. Sauvan, C. Graf, S. Harbarth O0299Digital droplet PCR to track SARS-CoV-2outbreak in a hospitaltransitionalcare unit L. Oberding* (Calgary, Canada), K. Linton, J. Kim, D. Pillai OS075 08:30 - 10:30 Hall H 2-Hour Oral Session Clinical PK/PD studies and TDM to improve dosing of anti- infectives ChairsBirgit Koch (Rotterdam, Netherlands) Sebastian Wicha (Hamburg, Germany) O0300Population toxicodynamics (TD) of intravenous polymyxin B (PB) in critically ill patients enrolled in an ongoing multi-centre prospective cohort study: prediction of incidence of acute kidney injury (AKI) G. Rao* (Chapel Hill, United States), P. Hanafin, A. Kwa, A. Zavascki, A. Sandri, M. Scheetz, C. Kubin, J. Shah, B. Cherng, M. Yin, J. Wang, L. Wang, A. Purcell, R. Nation, K. Kaye, J. Li O0301Development of modernisedAcinetobacter baumannii susceptibility guidance for recommended antimicrobial agents using pharmacometric approaches A. Lepak* (Madison, United States), B. Vanscoy, H. Sader, M. Trang, J. Hammel, S. Bhavnani, P. Ambrose, D. AndesNext >